|
| |
![]() |
![]() |
|
|
|
|
|
| |
|
| ||||||
|
|
|
Schedule of Laboratory Fees
BIOCHEMISTRY |
| (Applicable to all specimens except as denoted by B-blood, U-urine, F-faeces, C-CSF, A-amniotic fluid). | ||
| L059 | Acetaminophen | 25 |
| L001 | Acetone, qualitative | 3 |
| L002 | Acetone, quantitative | 35 |
| L003 | Addis count -U | 32 |
| L004 | Albumin, qualitative | 3 |
| L005 | Albumin, quantitative (excluded if globulin and/or protein electrophoresis done) | 5 |
| L006 | Alcohol, ethyl - quantitative | 25 |
| L008 | Alcohols, fractionation and quantification | 45 |
| L009 | Aldolase | 30 |
| L010 | Aldosterone. | 120 |
| L011 | Amino acids - one way chromatography - B.U. | 15 |
| L012 | Amino acids - two way chromatography - U | 30 |
| L013 | Amino acids, fractionation and quantitation | 200 |
| L014 | Amino acid nitrogen | 33 |
| L044 | Acid profile - organic (by GC-MS) | 200 |
| (Applicable to all specimens except as denoted by B-blood, U-urine, F-faeces, C-CSF, A-amniotic fluid). | ||
| L071 | Aminoglycosides (e.g., gentamicin, tobramycin) | 40 |
| L015 | Ammonia | 39 |
| L016 | Amniotic fluid scan | 20 |
| L017 | Amniotic fluid L/S ratio | 50 |
| L018 | Amylase | 5 |
| L021 | Androstenedione | 75 |
| L019 | Ascorbic acid (ascorbate) | 25 |
| L225 | Automated chemical analyzers with simultaneously functioning channels, single Sample (see Preamble, paragraph 15) | 5 |
| L026 | Barbiturates, quantitative | 35 |
| L027 | Barbiturates, fractionation and quantification (serum) - includes other drugs requiring similar methodology, e.g. tricyclic antidepressants | 60 |
| L028 | Bile microscopy | 4 |
| L029 | Bilirubin, qualitative - F | 3 |
| L030 | Bilirubin, total | 5 |
| L031 | Bilirubin, conjugated Blood gases (see listings on pages 11-12) |
10 |
| L037 | Blood volume - excluding injection of dye | 20 |
| L038 | Bromides | 15 |
| L039 | Bromosulphthalein (BSP) excluding injection of dye | 14 |
| L045 | Calcium | 5 |
| L046 | Calcium ionized | 20 |
| L047 | Calculus analysis - chemical, qualitative | 15 |
| L048 | Calculus analysis, qualitative and quantitative | 25 |
| L040 | Carbamazepine, quantitative (Tegretol) | 35 |
| L049 | Carotene | 16 |
| L050 | Catecholamines, total | 60 |
| L051 | Catecholamines, fractionated | 80 |
| L052 | Ceruloplasmin | 19 |
| L041 | Chlordiazepoxide, quantitative (Librium) | 40 |
| L053 | Chloride | 5 |
| L054 | Chloride (sweat) | 33 |
| L055 | Cholesterol, total - not to be claimed with L156 (see Preamble, paragraph 26) | 5 |
| L056 | Cholesterol, ester - not to be claimed with L156 | 14 |
| L057 | Cholinesterase - pseudo or true | 30 |
| (Applicable to all specimens except as denoted by B-blood, U-urine, | ||
| F-faeces, C-CSF, A-amniotic fluid). | ||
| L058 | Cholinesterase genotyping (includes pseudo, dibucaine and fluoride) | 50 |
| L060 | Carboxyhemoglobin | 15 |
| L061 | CO2 content, CO2 combining power, bicarbonate (measured, not calculated) | 5 |
| L062 | Chymotrypsin | 22 |
| L063 | Copper | 40 |
| L064 | Cortisol | 35 |
| L065 | Creatine (see Preamble, paragraph 8) | 26 |
| L066 | Creatine phosphokinase | 5 |
| L070 | Creatine phosphokinase, fractionation | 34 |
| L067 | Creatinine - not with L068 (see Preamble, paragraph 10) | 5 |
| L068 | Creatinine clearance | 15 |
| L075 | Crystal identification (x-ray powder diffraction analysis) | 30 |
| L069 | Cystine screening - U | 8 |
| L199 | Delta-aminolevulinic acid (ALA), quantitative - U | 25 |
| L074 | Diazepam, quantitative (Valium, Vivol) | 40 |
| L072 | Digoxin | 45 |
| L077 | Diphenylhydantoin, quantitative (Phenytoin, Dilantin) | 35 |
| L076 | Disopyramide | 35 |
| L078 | Drugs of abuse screen, urine | 68 |
| L079 | Broad spectrum toxicology screen, urine - includes confirmatory testing | 72 |
| L085 | Electrophoresis, serum - including total protein | 36 |
| L086 | Electrophoresis, other than serum - including total protein | 50 |
| L080 | Electrophoresis, serum - alone | 26 |
| L092 | Ethosuximide, quantitative (Zarontin) | 35 |
| L095 | Fat, total- F | 72 |
| L096 | Fat, differential - F | 92 |
| L097 | Fat and/or meat fibres (microscopic) - F | 6 |
| L098 | Fat (microscopic) - U | 6 |
| L099 | Fatty acids, free | 25 |
| L094 | Flurazepam, quantitative (Dalmane) | 40 |
| L105 | Galactose (per sample) | 16 |
| L106 | Galactose-l-phosphate uridyl transferase (quantitative) | 65 |
| L113 | Galactose-l-phosphate uridyl transferase (screening) | 10 |
| L107 | Gamma glutamyl transpeptidase | 5 |
| L109 | Gastric analysis titration (per sample) | 7 |
| (Applicable to all specimens except as denoted by B-blood, U-urine, | ||
| F-faeces, C-CSF, A-amniotic fluid). | ||
| L110 | Globulin (excluded if albumin and/or protein electrophoresis done) | 10 |
| L111 | Glucose, quantitative - not by dipstick (see Preamble, paragraph 4) | 5 |
| L112 | Glucose, semi-quantitative (dipstick if read with reflectance meter) | 3 |
| L104 | Glucose tolerance test (see Preamble, paragraph 4) | 30 |
| L103 | Glucose tolerance test in pregnancy (see Preamble, paragraph 4) | 24 |
| L114 | Glutathione | 20 |
| L115 | Glycoproteins | 60 |
| L093 | Glycosylated hemoglobin - HgbAl | 22 |
| L116 | Gold | 40 |
| L119 | Hexosaminidase A | 15 |
| L132 | Hemoglobin A2 by chromatography | 25 |
| L121 | 5HIAA screening - U | 9 |
| L122 | 5HIAA quantitation - U | 50 |
| L117 | High density lipoprotein cholesterol | 18 |
| L118 | Histamine | 90 |
| L123 | Homogentisic acid (homogentisate) - qualitative | 9 |
| L101 | Homovanillic acid (homovanillate), HVA | 60 |
| L124 | Hydroxybutyrate dehydrogenase | 10 |
| L125 | 17-Hydroxycorticosteroids - U | 34 |
| L126 | 17-Ketogenic steroids - U | 40 |
| L127 | 17-Ketosteroids, total - U | 34 |
| L128 | 17-Ketosteroids, fractionated - U | 80 |
| L129 | Hydroxyproline - B | 25 |
| L130 | Hydroxyproline, total - U | 90 |
| L131 | Hydroxyproline, total and free - U | 150 |
| L135 | Inulin clearance test | 40 |
| L136 | Inulin | 40 |
| L142 | Intestinal enzymes - qualitative | 6 |
| L143 | Intestinal enzymes - quantitative | 22 |
| L137 | Iodine protein bound | 21 |
| L139 | Iron, total -with iron binding capacity and per cent saturation - not to be claimed with L329 | 34 |
| L141 | Iso-citric dehydrogenase | 15 |
| L145 | Lactic acid (lactate) | 27 |
| L146 | Lactic dehydrogenase (L.D.H.), total | 10 |
| L147 | Lactic dehydrogenase fractionation | 29 |
| (Applicable to all specimens except as denoted by B-blood, U-urine, | ||
| F-faeces, C-CSF, A-amniotic fluid). | ||
| L148 | Lead | 40 |
| L149 | Leucine aminopeptidase | 15 |
| L150 | Lipase | 22 |
| L151 | Lipid (total) | 16 |
| L152 | Lipids (thin layer chromatography) | 30 |
| L153 | Lipoprotein, electrophoresis - not to be claimed with L156 | 20 |
| (see Preamble, paragraph 26) | ||
| L154 | Lipoprotein, ultracentrifugation | 50 |
| L155 | Lipoprotein lipase | 100 |
| L156 | Lipoprotein phenotyping (includes sample appearance, cholesterol, triglycerides, Lipoprotein electrophoresis and interpretation) - not to be claimed with L055, L153 or L243 | 40 |
| L157 | Lithium | 10 |
| L165 | Magnesium | 5 |
| L166 | Malic acid (malate) dehydrogenase | 15 |
| L167 | Melanin - U | 10 |
| L168 | Mercury | 30 |
| L169 | Metanephrines, total - U | 75 |
| L170 | Metanephrines, fractionated - U | 90 |
| L171 | Methemalbumin | 21 |
| L172 | Methemoglobin | 21 |
| L160 | Methotrexate (amethopterin) | 35 |
| L175 | Methylphenidate, quantitative (Ritalin) | 40 |
| L173 | Mucopolysaccharides - U | 25 |
| L174 | Myoglobin, qualitative - U | 30 |
| L161 | N-acetylprocainamide | 35 |
| L180 | 5' - Nucleotidase | 25 |
| L181 | Occult blood | 3 |
| L182 | Ornithine carbamoyl transferase | 15 |
| L183 | Osmolality (osmolarity) | 10 |
| L184 | Oxalic acid (oxalate) - U | 40 |
| L185 | P.A.H. clearance | 40 |
| L032 | pCO2 | 8 |
| L033 | pO2 arterial | 8 |
| L034 | pH | 7 |
| L035 | pCO2 , pO2 and pH in combination | 17 |
| L036 | pCO2 , pO2 pH- calculation of one or more of standard bicarbonate, base | |
| excess, etc (see Preamble, paragraph 9) | 3 |
|
| L187 | Phenothiazines, qualitative - U | 6 |
| (Applicable to all specimens except as denoted by B-blood, U-urine, F-faeces, C-CSF, A-amniotic fluid) | ||
| L188 | Phenothiazines, quantitative - U | 30 |
| L189 | Phenylalanine | 15 |
| L190 | Phosphatase, acid | 15 |
| NOTE: | L190 - no additional claim may be made for a repeat test using an Inhibitor (such as for prostatic acid phosphatase determination). | |
| L191 | Phosphatase, alkaline | 5 |
| L192 | Phosphatase, alkaline fractionation | 29 |
| L193 | Phospholipids | 30 |
| L194 | Phosphorus (inorganic phosphate) | 5 |
| L195 | Plasma clearing factor (Baker) | 35 |
| L196 | Plasma hemoglobin | 15 |
| L197 | Porphobilinogen (PBG), screen - U | 10 |
| L198 | Porphobilinogen (PBG), quantitative - U | 25 |
| L200 | Porphyrins, screen | 10 |
| L201 | Porphyrins, quantitation (copro, proto, uro) - U | 60 |
| L202 | Porphyrins, quantitation (copro, proto, uro) - B | 75 |
| L203 | Porphyrins, quantitation (copro, proto, uro) - F | 90 |
| L204 | Potassium | 5 |
| L205 | Pregnanediol - U | 70 |
| L206 | Pregnanetriol - U | 80 |
| L211 | Primidone, quantitative (Mysoline) | 35 |
| L212 | Procainamide | 35 |
| L213 | Propranolol | 35 |
| L208 | Protein, total - not to be claimed with L085 or L086 | 5 |
| L209 | PSP (Phenosulphonphthalein) | 15 |
| L210 | Pyruvic acid (pyruvate) | 27 |
| L215 | Quinidine | 18 |
| L216 | Reducing substances, identified by chromatography | 30 |
| L220 | Salicylate, qualitative | 5 |
| L221 | Salicylate, quantitative | 12 |
| L222 | SGOT (AST) | 5 |
| L223 | SGPT (ALT) | 5 |
| L226 | Sodium | 5 |
| L227 | Spectroscopic examination (any) | 20 |
| (Applicable to all specimens except as denoted by B-blood, U-urineF-faeces, C-CSF, A-amniotic fluid). | ||
| L228 | Sulfhemoglobin | 21 |
| L229 | Sulfonamides | 27 |
| L073 | Target drug testing, urine, qualitative or quantitative | 17 |
| L240 | Thiocyanates | 15 |
| L243 | Triglycerides - not to be claimed with L156 (see Preamble, paragraph 26) | 5 |
| L244 | Trypsin | 22 |
| L250 | Urea clearance | 15 |
| L251 | Urea nitrogen (B.U.N.) | 5 |
| L252 | Uric acid (urate) | 5 |
| L253 | Urinal Urinalysis, routine chemical (any of S.G., pH, protein, sugar, hemoglobin, ketones, urobilinogen, bilirubin, leukocyte esterase, nitrate) see Preamble, paragraph 4 | 5 |
| L254 | Urinalysis, microscopic examination of centrifuged specimen | 2 |
| L267 | Urobilin, qualitative - U | 7 |
| L256 | Urobilinogen, quantitative - U | 15 |
| L257 | Valproic acid (valproate) | 35 |
| L260 | Vitamin A | 30 |
| L261 | VMA, vanillylmandelic acid (vanillylmandelate) | 60 |
| L265 | Xylose absorption test (per specimen) | 6 |
| L266 | Zinc | 25 |
| L299 | Biochemical assays not included above | IC |
| NOTE: | Biochemical assays other than specifically listed are not a benefit as such until approved by the Ministry of Health. |
|
| |
|
| |
|
Call the ministry INFOline at 1-866-532-3161 (Toll-free in Ontario only) TTY 1-800-387-5559 Hours of operation : 8:30am - 5:00pm |
|
|
| |
|
| |
|
| Laboratory Service Fees Menu
|
|